Peptide switch is essential for Sirt1 deacetylase activity

Area of Science:

• Biochemistry
• Molecular Biology
• Cellular Biology

Background:

• Sirtuins (Sirt1-7) are NAD(+)-dependent deacetylases in mammals.
• The Sirt1 deacetylase core alone lacks catalytic activity.
• Understanding Sirt1 regulation is key for therapeutic development.

Purpose of the Study:

• To identify the region responsible for Sirt1 catalytic activity.
• To investigate the interaction between Sirt1's regulatory regions and its core.
• To explore the therapeutic potential of targeting Sirt1.

Main Methods:

• Identification and characterization of the Essential for Sirt1 Activity (ESA) region.
• Analysis of DBC1 interaction with Sirt1 and the ESA region.
• Development and application of an ESA mutant peptide for Sirt1 inhibition.
• Assessment of Sirt1 inhibition on prostate cancer cell chemosensitivity.

Main Results:

• A 25 amino acid sequence (ESA) in the C-terminal domain is essential for Sirt1 catalytic activity.
• The ESA region acts as an 'on switch' by interacting with the deacetylase core.
• The endogenous inhibitor DBC1 competes with ESA for binding to the deacetylase core.
• An ESA mutant peptide inhibits Sirt1 in trans and increases chemosensitivity in prostate cancer cells.

Conclusions:

• The ESA region is critical for Sirt1 function and represents a novel regulatory mechanism.
• Targeting the ESA region offers a potential therapeutic strategy for modulating Sirt1 activity.
• Inhibition of Sirt1 via the ESA region enhances chemosensitivity in androgen-refractory prostate cancer.